PMID- 26536165
OWN - NLM
STAT- MEDLINE
DCOM- 20160622
LR  - 20151127
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 9
IP  - 1
DP  - 2016
TI  - Cabozantinib for the treatment of progressive metastatic medullary thyroid 
      cancer.
PG  - 69-79
LID - 10.1586/17512433.2016.1102052 [doi]
AB  - Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other 
      receptor tyrosine kinases, such as KIT, AXL and FLT3. Its efficacy against MTC 
      has been demonstrated in a prospective, randomized, placebo-controlled study 
      (EXAM). Cabozantinib comparing to placebo significantly prolonged progression 
      free survival both in hereditary and sporadic MTC, 11.2 vs 4.0 months, 
      respectively. Final analysis showed no global differences in overall survival 
      (OS) between cabozantinib and placebo. However, in a subgroup with RET M918T 
      mutation the difference in OS was significant: 44.3 vs 18.9 months, respectively. 
      Among the most frequent cabozantinib-related adverse events (AEs), observed in 
      >30% of patients were diarrhea, palmar-plantar erythrodysesthesia, decreased 
      weight, decreased appetite, nausea, fatigue, dysgeusia, hair color changes and 
      hypertension. Expert Commentary: Cabozantinib constitutes an effective treatment 
      option with acceptable toxicity in MTC patients showing either germinal or 
      sporadic tumor RET M918T mutation as the drug prolonged OS in these subjects.
FAU - Krajewska, Jolanta
AU  - Krajewska J
AD  - a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology , Gliwice , Poland.
FAU - Olczyk, Tomasz
AU  - Olczyk T
AD  - a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology , Gliwice , Poland.
FAU - Jarzab, Barbara
AU  - Jarzab B
AD  - a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie 
      Memorial Cancer Center and Institute of Oncology , Gliwice , Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151104
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 1C39JW444G (cabozantinib)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Anilides/adverse effects/pharmacology/*therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/pharmacology/therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy/genetics/pathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Humans
MH  - Mutation
MH  - Neoplasm Metastasis
MH  - Protein Kinase Inhibitors/adverse effects/pharmacology/*therapeutic use
MH  - Proto-Oncogene Proteins c-ret/genetics
MH  - Pyridines/adverse effects/pharmacology/*therapeutic use
MH  - Survival Rate
MH  - Thyroid Neoplasms/*drug therapy/genetics/pathology
OTO - NOTNLM
OT  - RET M918T mutation
OT  - TKI
OT  - VEGFR inhibitor
OT  - cabozantinib
OT  - medullary thyroid cancer
EDAT- 2015/11/05 06:00
MHDA- 2016/06/23 06:00
CRDT- 2015/11/05 06:00
PHST- 2015/11/05 06:00 [entrez]
PHST- 2015/11/05 06:00 [pubmed]
PHST- 2016/06/23 06:00 [medline]
AID - 10.1586/17512433.2016.1102052 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2016;9(1):69-79. doi: 10.1586/17512433.2016.1102052. 
      Epub 2015 Nov 4.